There are fewer Black men in US medical schools today than in 1970, although their contributions are key to building medicine’s capacity to equitably promote healing.
AMA J Ethics. 2021;23(12):E919-925. doi:
10.1001/amajethics.2021.919.
Mark C. Henderson, MD, Charlene Green, PsyD, and Candice Chen, MD, MPH
Focus on diversity is critical, yet most US schools have failed to achieve racial-ethnic or economic diversity representative of the general US population.
AMA J Ethics. 2021;23(12):E965-974. doi:
10.1001/amajethics.2021.965.
Deficit-focused interventions undermine appreciation of the value students and physicians with minoritized identities bring to medicine’s capacity to motivate equity.
AMA J Ethics. 2021;23(12):E975-980. doi:
10.1001/amajethics.2021.975.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"